rafaelnlins / Shutterstock.com

13 September 2024NewsBiotechnologySarah Speight

Sanofi signs global rights deal to develop rare cancer therapy

Sanofi will be responsible for global commercialisation of the medicine, used to treat neuroendocrine tumours | Pharma giant will pay up to $320m plus royalties to two biotech companies.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Sanofi subsidiary sues Sarepta over gene therapy

30 July 2024 Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.

Unified Patent Court: The cases, the numbers and what the future holds

27 June 2024 In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.

More on this story

Sanofi subsidiary sues Sarepta over gene therapy

30 July 2024 Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.

Unified Patent Court: The cases, the numbers and what the future holds

27 June 2024 In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.

More on this story

Sanofi subsidiary sues Sarepta over gene therapy

30 July 2024 Massachusetts biotech giants clash as Genzyme alleges Sarepta's Elevidys infringes on key gene therapy patents | Despite the dispute, Elevidys $200M in sales and recent FDA approvals show success.

Unified Patent Court: The cases, the numbers and what the future holds

27 June 2024 In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.

More features

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Bristol Myers Squibb leader named INTA 2025 president

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks